BDR Pharmaceuticals Internationals Pvt. Ltd.

BDR Pharmaceuticals Internationals Pvt. Ltd.

BDR Pharmaceuticals Internationals Pvt. Ltd.

May 2022

Announced Date: May 2022

Value: USD 100 million

o3 Capital advises BDR Pharmaceuticals on its fund raise from Multiples Alternate Asset Management, State Bank of India and other investors

We are pleased to announce that our client, BDR Pharmaceuticals Internationals Pvt. Ltd. (“BDR Pharma”), has successfully raised equity funding to the tune of Rs 750 Cr for ~10% stake from Multiples Alternate Asset Management (“Multiples”), State Bank of India (“SBI”) and other investors in two separate transactions.

Founded by Dharmesh Shah in 2003, BDR Pharma is an integrated complex generics manufacturer specializes in therapeutic areas of Oncology, Critical Care, Neurology, Gynecology and Covid-19 drugs. It has a proven track record of commercialization of complex molecules at a competitive price and is a partner of choice to leading formulations players like Sun, CIPLA, Glenmark, Dr Reddy’s, Intas, Alkem, Lupin etc.
Multiples is an India-based private equity firm with close to $1.8 bn under management and a portfolio of 23 companies across three funds.

The transaction will help BDR Pharma to fund new product development in both existing and new therapies and to expand into new geographies, apart from strengthening its manufacturing capabilities.

Mr. Dharmesh Shah, Chairman and MD, BDR Pharma said, “Multiples is an active investor in the pharmaceuticals sector and has a strong track record of partnering with visionary entrepreneurs and management teams in helping them in their transformation journeys. We are looking forward to accelerating our growth journey with trusted investors having a deep understanding of the sector, and regulatory environment and who bring first-hand experience in working with innovative, high-growth companies.”

Mr. Manish Gaur, MD and Head of healthcare, Multiples said, “BDR Pharma has a strong reputation for being an innovation partner of choice for leading Indian companies on the back of its excellent product development capabilities. Under the visionary leadership of Dharmesh Bhai, the Company has built a strong business in Indian as well as overseas markets.”

On the transaction, Prasanna Bora, Director, o3 Capital said, “Under the leadership of Dharmesh Shah, Dheer Shah and Raheel Shah are building a nimble footed, fast growing business in complex generics. I am sure that in partnership with Multiples and other investors, BDR Pharmaceuticals would scale new heights.”

o3 Capital acted as the exclusive financial advisor to BDR Pharma on the transaction.